对瘤性NRAS驱动Nevi的RNA疗法诱导了亡
Dale Bryant1, Sara Barberan-Martin1, Ruhina Maeshima2
1Mosaicism and Precision Medicine Laboratory, The Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
用小干扰RNA (siRNA) 准瘤性NRASQ61K有效地抑制了良性黑色细胞结核细胞. 这种方法诱导了亡并减少了癌症发病率,显示出治疗RAS驱动的良性瘤的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 瘤性RAS变体是各种癌症和良性病变的关键驱动因素,如黑色细胞瘤.
- 由于下游途径抑制剂的困难,直接向瘤性RAS一直是具有挑战性的.
研究的目的:
- 为了研究小干扰RNA (siRNA) 针对NRASQ61K变异在原发性黑色细胞神经细胞中的有效性.
- 探索NRASQ61K抑制的下游效应,包括其对细胞亡和内质网膜应激的影响.
主要方法:
- 利用了针对NRASQ61K变异的siRNA在初级黑色素细胞神经细胞中.
- 研究了ARL6IP1的表达及其在亡中的作用.
- 在脂质纳米颗粒中封装的siRNA被施用给黑色细胞瘤的人性化小鼠模型.
主要成果:
- 在原始细胞中实现了对瘤性NRASQ61K的有效抑制.
- siRNA治疗导致ARL6IP1表达的显著减少,并触发了亡级联.
- 在小鼠模型中,siRNA的体内输送导致了NRAS的淘汰,并证明了黑色细胞瘤的减少.
结论:
- 通过RAS介导的对亡的保护有助于NRAS驱动的黑色细胞瘤的持续.
- 向siRNA代表了对RAS驱动良性瘤的有前途的治疗策略,可能减少癌症发病率.
更多相关视频
05:45In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Intrinsic Apoptotic Pathway
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene
Ras is a...
Nucleotide Excision Repair
